<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38099372</article-id><article-id pub-id-type="pmc">PMC467027</article-id>
<article-id pub-id-type="publisher-id">IJO-72-393</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_914_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The use of calprotectin and other inflammatory parameters in the investigation of pseudoexfoliation syndrome concomitant glaucoma and systemic diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yasar</surname><given-names>Erdogan</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Erdal</surname><given-names>Huseyin</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Tuncer</surname><given-names>Sibel Cigdem</given-names></name><xref rid="aff3" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yagc&#x00131;</surname><given-names>Betul Akbulut</given-names></name><xref rid="aff4" ref-type="aff">3</xref></contrib></contrib-group><aff id="aff1">Ophtalmology Clinic, Afyonkarahisar Fair Hospital, Afyonkarahisar, Turkey</aff><aff id="aff2"><label>1</label>Department of Medical Genetics, Aksaray University Medicine Faculty, Aksaray, Turkey</aff><aff id="aff3"><label>2</label>Department of Biochemistry, Aksaray University Medicine Faculty, Aksaray, Turkey</aff><aff id="aff4"><label>3</label>Ophtalmology Clinic, Aksaray University Training and Research Hospital, Aksaray, Turkey</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Erdogan Yasar, Afyonkarahisar Fair Hospital, Ophtalmology Clinic, Afyonkarahisar, Turkey. E-mail: <email xlink:href="dr.e.yasar@gmail.com">dr.e.yasar@gmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2023</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S393</fpage><lpage>S397</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2023</year></date><date date-type="rev-recd"><day>16</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2023 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>The present study aimed to investigate the value of calprotectin and other inflammatory parameters in patients with glaucoma and systemic diseases accompanying pseudoexfoliation syndrome (PEX-S).</p></sec><sec id="st2"><title>Methods:</title><p>This prospective study included 45 PEX-S patients and 45 non-PEX control patients. Patients were investigated for the presence of glaucoma, cardiovascular disease (CVD), ischemic brain disease (IBD), Alzheimer&#x02019;s disease, and neurosensory hearing loss (NSHL). After excluding diseases that may affect inflammatory parameters, a detailed biomicroscopic examination, and blood tests were performed for the patients.</p></sec><sec id="st3"><title>Results:</title><p>Glaucoma, CVD, NVK, Alzheimer&#x02019;s disease, and NSHL were high in the PEX-S group (<italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> = 0.04, and <italic toggle="yes">P</italic> = 0.03, respectively). Calprotectin, ferritin, neutrophil-to-platelet ratio, and lymphocyte-to-platelet ratio were found to be high in the PEX-S group (<italic toggle="yes">P</italic> &#x0003c; 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> &#x0003c; 0.01, and <italic toggle="yes">P</italic> &#x0003c; 0.01, respectively). On evaluating the relationship between PEX-S and glaucoma and systemic diseases, it was found that elevated calprotectin increased the risk of glaucoma by 4.36 times and elevated neutrophil-to-lymphocyte ratio (NLR) increased the risk of CVD by 3.23 times in PEX-S patients (<italic toggle="yes">P</italic> = 0.02 and <italic toggle="yes">P</italic> = 0.03, respectively).</p></sec><sec id="st4"><title>Conclusion:</title><p>This study demonstrated the value of calprotectin elevation in detecting concomitant glaucoma in PEX-S patients and, in addition, the value of NLR elevation in detecting concomitant CVD.</p></sec></abstract><kwd-group><kwd>Calprotectin</kwd><kwd>glaucoma</kwd><kwd>neutrophil to lymphocyte</kwd><kwd>pseudoexfoliation</kwd></kwd-group></article-meta></front><body><p>Pseudoexfoliation (PEX) is an age-related disease in which abnormal fibrillar extracellular material is produced and deposited in the anterior segment of the eye and various extraocular tissues, as well as in the cerebral meninges, gallbladder, lung, heart, and kidney.[<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref>] PEX syndrome (PEX-S) is, therefore, now recognized as an ocular disorder as well as a systemic disease. Various studies indicate that oxidative damage, genetic predisposition, and inflammation play a crucial role in the pathogenesis of the disease.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref>] In previous studies, elevated levels of inflammatory parameters such as homocysteine, tumor necrosis factor (TNF)-&#x003b1;, nitric oxide, high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-1, IL-6, red cell distribution (RDW), and neutrophil-to-lymphocyte ratio (NLR) were found in PEX-S patients.[<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>]</p><p>The prevalence of PEX-S ranges between 0% and 38% and depends on ethnic and geographic factors.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref>] We found its prevalence to be 5% in our prevalence study conducted in Eskisehir, Turkey.[<xref rid="R12" ref-type="bibr">12</xref>] Its concomitance with other systemic diseases such as hypertension (HT), cardiovascular disease (CVD), myocardial infarction (MI), peripheral vascular disease, ischemic brain disease (IBD), stroke, neurosensory hearing loss (NSHL), and depression suggests that PEX-S is a part of systemic diseases.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref>]</p><p>A relatively new inflammatory marker, calprotectin (CLP), is also a 36-kDa protein and a member of the calcium-modulated family of S100 proteins.[<xref rid="R15" ref-type="bibr">15</xref>] CLP, which has recently been shown to be a sensitive inflammation marker, is mostly formed in neutrophils and constitutes approximately 60% of the cytosolic protein content in neutrophils and is released from the body during inflammation.[<xref rid="R16" ref-type="bibr">16</xref>] Elevated CLP has been detected in rheumatoid arthritis, inflammatory bowel disease, chronic sinusitis, various types of cancer, and some inflammatory and infectious diseases such as uveitis and sepsis.[<xref rid="R17" ref-type="bibr">17</xref><xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>]</p><p>To our knowledge, there is no study on serum CLP in relation to PEX-S and its comorbidities in the literature. Therefore, this study is the first study to investigate other inflammation markers.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>A total of 45 patients diagnosed with PEX-S between March and May 2022 at Aksaray University Training and Research Hospital Ophthalmology Outpatient Clinic were followed up. The control group consisted of 45 patients who consulted the ophthalmology outpatient clinic and did not get a PEX diagnosis in the examination. The demographic information of the study and control groups was obtained from the hospital automation system. Informed written consent was obtained from all participants. The study was conducted in accordance with the principles of the Declaration of Helsinki, and the local ethics committee approval was obtained.</p><p>The exclusion criteria were history of active ocular or systemic infection; presence of inflammatory, rheumatologic, and autoimmune diseases; history of hematologic diseases such as neutrophilia, neutropenia, lymphocytosis, and lymphopenia; history of pancreatic, liver, or kidney disease; malignancies; neurodegenerative diseases; iridocyclitis; presence of corneal, lens, and pupillary diseases that would prevent visualization of the anterior and posterior segments; diagnosis of other non-PEX glaucoma types; and smoking history.</p><p>The general and ocular medical history and regular medication use of the participants were investigated in detail. Patients&#x02019; information, such as age, gender, presence of a diagnosed chronic disease, regular medication use, CVD, MI, history of angioplasty, cerebrovascular disease, history of stroke, hearing loss, presence of Alzheimer&#x02019;s disease, diagnosis of glaucoma, and use of antiglaucoma eye drops, were obtained and recorded. Participants were questioned about their current medications and their diseases, which were subsequently checked locally in the hospital information system and generally in the national information system. Patients were questioned about their use of medication for coronary artery disease, as well as their history of MI, angioplasty, bypass, and peripheral vascular disease, and the presence of any of these factors was considered as the presence of CVD. In neurologic terms, patients were asked about their history of previous stroke and medication use due to IBD, and their radiologic images were studied. The presence of these factors was considered as the presence of IBD. In terms of Alzheimer&#x02019;s disease, patients were asked about the medication they used, which was subsequently checked on the information systems. The presence of any such medication was considered as the presence of Alzheimer&#x02019;s disease. In terms of NSHL, patients were asked to determine if they had hearing loss. For patients who reported that they experienced hearing loss, the patient-reported information was checked on the information systems. Once verified, these patients were recorded as NSHL-present.</p><sec id="sec2-1"><title>Sample collection of the study</title><p>Blood samples from the PEX-S and the control groups were collected into vacuum biochemistry tubes containing ethylenediaminetetraacetic acid (EDTA). The study samples were centrifuged at 1500 <italic toggle="yes">g</italic> for 10 min. The serum samples obtained after separation were aliquoted into Eppendorf tubes and stored in a deep freezer at &#x02212;80&#x000b0;C until the time of analysis. Routine biochemistry parameters such as lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and albumin levels were studied using a biochemistry analyzer (Siemens AdviaCentaur) in Aksaray University Training and Research Hospital Biochemistry Laboratory. Blood for complete blood count (CBC) was collected from the same patients into a hemogram tube with ethylenediaminetetraacetic acid (EDTA), and the calculation was performed on a hematology analyzer. CLP levels were measured on an ELx-800 (BioTek<sup>&#x000ae;</sup>) using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Elabscience Human CLP ELISA Kit, catalog number: E-EL-H2357), and values were expressed as ng/mL.</p><p>Examination of ocular anterior and posterior segments was performed using a biomicroscope (Topcon, Japan). Intraocular pressure (IOP) was measured by rebound tonometry (I-care TA01i, SN: 1108CA076; I-care, Vantaa in Finland); the mean of five measurements provided by the device was recorded for both eyes in each patient. PEX-S patients were recorded as glaucoma-present if they were on antiglaucomatous medication and did not have other forms of glaucoma. In addition, if no antiglaucomatous agent was used, patients with IOP &#x0003e;22, vertical Cup/Disc (C/D) ratio &#x02265;0.7 or C/D ratio of asymmetry between the two eyes &#x0003e;0.2, and glaucoma-specific visual field defect or patients with retinal nerve fiber defect compatible with glaucoma on optic cohorence tomography (OCT, Optovue) were accepted as glaucoma patients (Humphrey, Zeiss Visual Field Device). Both pupils were then dilated using mydriatic drops (0.5% tropicamide). The lens and other anterior segment structures were re-evaluated for PEX 30 min after instillation. PEX-S was diagnosed in the presence of white-gray extracellular material (EM) at the pupillary margin and anterior lens capsule.</p></sec><sec id="sec2-2"><title>Statistical analysis</title><p>The number of groups (<italic toggle="yes">n</italic>), mean, standard deviation, minimum (Min), and maximum (Max) values will be given in the statistical description of the groups. The normality of the data distribution was evaluated by Shapiro&#x02013;Wilk test, and the data was found to have a normal distribution. Student&#x02019;s <italic toggle="yes">t</italic>-test was used to compare the mean values of a variable observed in two different situations. Differences between the groups at <italic toggle="yes">P</italic> &#x0003c; 0.05 were considered significant. The Chi-square test was used to compare the means of categorical variables. Binomial logistic regression analysis was performed to calculate the odds ratios of the association between descriptive variables. Statistical Package for the Social Sciences (SPSS) version 23.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>The mean age of the 45 PEX-S patients included in the study was 64.3 &#x000b1; 6.7 years, and the mean age of the control group of 45 patients was 67.4 &#x000b1; 4.9 years. The PEX-S group consisted of 27 males and 18 females, while the control group consisted of 23 males and 22 females. There was no statistically significant difference between the groups in terms of age and gender (<italic toggle="yes">P</italic> &#x0003e; 0.05). In addition, HT was found in 22 (48.8%) and diabetes mellitus (DM) in 10 (22.2%) of the PEX-S patients. HT was found in 16 (31%) and DM in nine (20%) patients of the control group, and no significant difference was found between the groups (<italic toggle="yes">P</italic> &#x0003e; 0.05).</p><p>Of the 45 patients with PEX-S, 11 (24.4%) had glaucoma, 16 (35.6%) had CVD, six (13.3%) had IBD, eight (17.8%) had Alzheimer&#x02019;s disease, and 13 (28.9%) had NSHL. On the other side, of the 45 control patients without PEX-S, two (4.4%) had glaucoma, four (8.9%) had CVD, one (2.2%) had IBD, two (4.4%) had Alzheimer&#x02019;s disease, and five (11.1%) had NSHL. As concomitant diseases accompanying PEX-S, the rates of glaucoma and CVD were significantly higher in the PEX-S group than in the control group (<italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> = 0.04, and <italic toggle="yes">P</italic> = 0.03, respectively).</p><p>Of the 45 PEX-S patients, 24 (53.3%) had unilateral PEX and 21 (46.7%) had bilateral PEX, and there was no difference between the groups in terms of involvement type (<italic toggle="yes">P</italic> &#x0003e; 0.05). Of the 26 cases with unilateral involvement, 14 had PEX involved in the right eye and 12 in the left eye and the difference was not significant (<italic toggle="yes">P</italic> &#x0003e; 0.05). Comparison of inflammatory parameters including CLP, CRP, ferritin, albumin, LDH, leukocyte, neutrophil-to-platelet ratio (NPR), lymphocyte-to-platelet ratio (LPR), NLR, and RDW between the groups with and without PEX-S is shown in detail in <xref rid="IJO.IJO_914_23-T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="IJO.IJO_914_23-T1"><label>Table 1</label><caption><p>Comparison of inflammatory parameters in the groups with and without PEX-S</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">PEX+</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">PEX&#x02212;</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Calprotectin (&#x003bc;g/mg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>1.22&#x000b1;0.51</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>0.86&#x000b1;0.21</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.65&#x000b1;4.89</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.62&#x000b1;0.98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferritin (mg/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>59.93&#x000b1;18.32</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>38.07&#x000b1;1</bold>
<bold>3.66</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (g/dL)<break/>LDH (U/L)<break/>Leukocyte</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.91&#x000b1;1.08<break/>74.85&#x000b1;8.78<break/>7.21&#x000b1;2.34</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.89&#x000b1;0.96<break/>51,32&#x000b1;5.82<break/>6.43&#x000b1;1.78</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.28<break/>0.16<break/>0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">N/P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>1.94&#x000b1;0.86</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>7.18</bold>
<bold>&#x000b1;1.00</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">L/P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>0.98&#x000b1;0.41</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>1.33&#x000b1;0.43</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">N/L</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.32&#x000b1;1.05</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.96+0.65</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">RDW (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.23&#x000b1;1.19</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.34&#x000b1;1.28</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.69</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>Bold values are statistically significant, PEX=pseudoexfoliation, LDH=lactate dehydrogenase, N/P=neutrophil/platelet, L/P=Lenfosit/Platelet, N/L=N&#x000f6;trofil/Lenfosit, RDW=red blood cell distribution width, OR=odds ratio</p></fn></table-wrap-foot></table-wrap><p>This detailed comparison showed that CLP, ferritin, NPR, and LPR values were significantly higher in the PEX-S group (<italic toggle="yes">P</italic> &#x0003c; 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> &#x0003c; 0.01, and <italic toggle="yes">P</italic> &#x0003c; 0.01, respectively). Although CRP, LDH, and NLR were higher and albumin was lower in the PEX-S group compared to the control group, these differences were not statistically significant (<italic toggle="yes">P</italic> = 0.30, <italic toggle="yes">P</italic> = 0.16, <italic toggle="yes">P</italic> = 0.74, and <italic toggle="yes">P</italic> = 0.28, respectively).</p><p>The relationship between inflammatory parameters including CLP, CRP, ferritin, albumin, LDH, leukocyte, NPR, LPR, NLR, and RDW and the comorbidities of glaucoma, CVD, IBD, Alzheimer&#x02019;s disease, and NSHL in the PEX-S group was evaluated by binomial logistic regression, and the results are shown in <xref rid="IJO.IJO_914_23-T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="IJO.IJO_914_23-T2"><label>Table 2</label><caption><p>The relationship of ocular and systemic diseases accompanying PEX-S with inflammatory parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Glaucoma<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">CVD<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">IBD<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Alzheimer<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">NSHL<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">OR</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Calprotectin (&#x003bc;g/mg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.36</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.38</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.43</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.03</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferritin (mg/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.37</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.03</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (g/dl)<break/>LDH (U/L)<break/>Leukocyte</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.79<break/>0.71<break/>0.42</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.05<break/>1.01<break/>0.87</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.35<break/>0.97<break/>0.38</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.21<break/>1.00<break/>0.87</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00<break/>0.99<break/>0.99</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.02<break/>0.68<break/>0.37</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.79<break/>0.87<break/>0.91</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.05<break/>1.01<break/>1.03</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.15<break/>0.96<break/>0.87</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.79<break/>1.01<break/>0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">N/P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.94</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.35</td></tr><tr><td align="left" rowspan="1" colspan="1">L/P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.34</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">N/L</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.48</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">RDW (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.80</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.86</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>CVD: Cardiovascular Disease, IBD: Ischemic Brain Disease, NSHL: Neurosensory Hearing Loss, LDH: Laktat Dehidrogenez, N/P: N&#x000f6;trofil/Platelet, L/P: Lenfosit/Platelet, N/L: N&#x000f6;trofil/Lenfosit, RDW: Red Blood Cell distributionwidth, OR: OddsRatio</p></fn></table-wrap-foot></table-wrap><p>Evaluation of the relationship between the inflammatory parameters and comorbid ocular and systemic diseases in PEX-S patients revealed a 4.36-fold increased risk of glaucoma with elevated CLP and a 3.23-times increased risk of CVD with elevated neutrophil and platelet counts (<italic toggle="yes">P</italic> = 0.02 and <italic toggle="yes">P</italic> = 0.03, respectively).</p></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>PEX-S is a multifactorial disease and genetic factors, oxidative damage, and inflammation have been found to be involved in its etiopathogenesis in various studies.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref>] PEX-S is now recognized as a systemic disease because PEX material has been demonstrated in the eye and systemically in various tissues. In this study, we investigated the relationship between inflammatory parameters and comorbid ocular and systemic diseases in PEX-S patients. On further analysis, CLP was significantly correlated with concomitant glaucoma, and NPR was significantly correlated with concomitant CVD.</p><p>PEX-S has been associated with coronary artery disease, angina pectoris, HT, MI, aortic aneurysm, stroke, sensorineural hearing loss, peripheral artery disease, and depression in many studies.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref>] Similar to our study, glaucoma, CVD, IBD, Alzheimer&#x02019;s disease, and NSHL were significantly higher in the PEX-S group (<italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> = 0.04, and <italic toggle="yes">P</italic> = 0.03, respectively).</p><p>In many studies, elevation of inflammatory parameters, such as homocysteine, TNF-&#x003b1;, transforming growth factor (TGF)-&#x003b2;, nitric oxide, hs-CRP, IL-1, IL-6, and IL-17, has been found in patients with PEX-S.[<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>] In our study, CLP, ferritin, NPR, and LPR values were significantly higher in the PEX-S group (<italic toggle="yes">P</italic> &#x0003c; 0.01, <italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">P</italic> &#x0003c; 0.01, and <italic toggle="yes">P</italic> &#x0003c; 0.01, respectively). In addition, although CRP, LDH, and NLR were high and albumin was low in the PEX-S group, these differences were not statistically significant (<italic toggle="yes">P</italic> = 0.30, <italic toggle="yes">P</italic> = 0.16, <italic toggle="yes">P</italic> = 0.74, and <italic toggle="yes">P</italic> = 0.28, respectively). In addition to the relatively low number of patients, this may be an evidence that since PEX-S is more of a localized inflammatory disease, not every test showing systemic inflammation can demonstrate the presence of PEX-S&#x02013;related inflammation.</p><p>In recent studies, the relationship between inflammatory parameters and PEX-S comorbidities has been demonstrated. Oh <italic toggle="yes">et al</italic>.[<xref rid="R8" ref-type="bibr">8</xref>] reported that elevated NLR in PEX-S patients was an important parameter in detecting concomitant CVD, and that the incidence of CVD increased due to impaired endothelial function by the PEX material accumulated in vascular tissues. Bashir <italic toggle="yes">et al</italic>.[<xref rid="R9" ref-type="bibr">9</xref>] found that RDW elevation was an important parameter in the detection of glaucoma in PEX-S patients and explained this relationship as the suppression of erythrocyte maturation as a result of increased cytokines in PEX-S and the appearance of size differences with juvenile erythrocytes entering the circulation. In the present study, the relationship between CLP and glaucoma and between elevated NLO and CVD in PEX-S patients was strongly demonstrated. In PEX-S patients with elevated CLP, the risk of concomitant glaucoma increased by 4.36 times, and in PEX-S patients with elevated NPR, the risk of CVD increased by 3.23 times (<italic toggle="yes">P</italic> = 0.02 and <italic toggle="yes">P</italic> = 0.03, respectively).</p><p>CLP is a protein secreted extracellularly from neutrophils and monocytes or released after cell lysis or death, and its elevation has been reported in certain inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, chronic sinusitis, various types of cancer, and uveitis.[<xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref><xref rid="R17" ref-type="bibr">17</xref><xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref>] CLP is involved in chemotaxis, phagocyte migration, and neutrophil and macrophage modulation and has an important role in the pathogenesis of inflammatory diseases, and has therefore been used as a sensitive marker in the early detection of some infections.[<xref rid="R17" ref-type="bibr">17</xref><xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] Elevated NPR is more of a vascular marker and is associated with increased mortality after MI, as a marker of poor prognosis in aortic dissection and is significantly correlated with hemorrhagic expansion in spontaneous intracerebral hemorrhages.[<xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref>]</p><p>Oxidative stress (OS) and hypoxia occurring in the tissue are the main factors activating the pathophysiologic process in PEX-S.[<xref rid="R3" ref-type="bibr">3</xref>] OS caused by impaired local oxidative/antioxidative balance results in local inflammation, thereby leading to proinflammatory cytokines being released and the inflammatory reaction being activated.[<xref rid="R26" ref-type="bibr">26</xref><xref rid="R27" ref-type="bibr">27</xref>] In fact, this inflammation is the outcome of the cumulative effect of OS and impaired endothelial function. Since inflammation in PEX-S is more of a localized inflammation, sensitive inflammatory markers that specifically indicate localized inflammation will be more useful to detect the inflammation present. The high detection of NPR and CLP in our PEX article and the high detection of NLR in previous PEX studies may suggest that neutrophils may be involved in the inflammation process in PEX-S.</p><p>The limitations of our study include the relatively limited number of patients and the fact that inflammatory parameters were analyzed only in blood, but not in aqueous humor fluid. The fact that hs-CRP, a more sensitive indicator of inflammation, was not used instead of CRP is another limitation.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>In conclusion, this study demonstrated the significance of elevated CLP in detecting concomitant glaucoma and of NLR in detecting CVD in PEX-S patients. Further studies with a large number of patients and sensitive agents are needed to determine the mechanism and types of inflammatory factors involved in the pathogenesis of PEX-S, which is associated mostly with local inflammation.</p><sec id="sec2-3"><title>Consent form</title><p>Written informed consent was obtained from all participants after the study procedures had been fully explained t o them.</p></sec><sec sec-type="data-availability" id="sec2-4"><title>Data availability statement</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restriction.</p></sec><sec sec-type="funding-statement" id="sec2-5"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-6"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Streeten</surname><given-names>BW</given-names></name>
<name><surname>Li</surname><given-names>ZY</given-names></name>
<name><surname>Wallace</surname><given-names>RN</given-names></name>
<name><surname>Eagle</surname><given-names>RC</given-names><suffix>Jr</suffix></name>
<name><surname>Keshgegian</surname><given-names>AA</given-names></name></person-group><article-title>Pseudoexfoliative fibrilliopathy in visceral organs of a patient with pseudoexfoliation syndrome</article-title><source>Arch Ophtalmol</source><year>1992</year><volume>110</volume><fpage>1757</fpage><lpage>62</lpage></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schl&#x000f6;tzer-Schrehardt</surname><given-names>UM</given-names></name>
<name><surname>Koca</surname><given-names>MR</given-names></name>
<name><surname>Naumann</surname><given-names>GO</given-names></name>
<name><surname>Volkholz</surname><given-names>H</given-names></name></person-group><article-title>Pseudoexfoliation syndrome ocular manifestation of a systemic disorder?</article-title><source>Arch Ophthalmol</source><year>1992</year><volume>110</volume><fpage>1752</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1463418</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schl&#x000f6;tzer-Schrehardt</surname><given-names>U</given-names></name>
<name><surname>Lommatzsch</surname><given-names>J</given-names></name>
<name><surname>K&#x000fc;chle</surname><given-names>M</given-names></name>
<name><surname>Konstas</surname><given-names>AG</given-names></name>
<name><surname>Naumann</surname><given-names>GO</given-names></name></person-group><article-title>Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>1117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">12601038</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yaz</surname><given-names>Y</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>N</given-names></name>
<name><surname>Ayd&#x00131;n Yaz</surname><given-names>Y</given-names></name>
<name><surname>&#x000c7;ilingir</surname><given-names>O</given-names></name>
<name><surname>Y&#x000fc;ksel</surname><given-names>Z</given-names></name>
<name><surname>Mutlu</surname><given-names>F</given-names></name></person-group><article-title>Three single nucleotide polymorphisms of LOXL1&#x02019; in a Turkish population with pseudoexfoliation syndrome and pseudoexfoliation glaucoma</article-title><source>Turk J Ophthalmol</source><year>2018</year><volume>48</volume><fpage>215</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">30405941</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okutucu</surname><given-names>M</given-names></name>
<name><surname>Findik</surname><given-names>H</given-names></name>
<name><surname>Aslan</surname><given-names>MG</given-names></name>
<name><surname>Arpa</surname><given-names>M</given-names></name></person-group><article-title>Is Netrin-1 deficiency responsible for &#x00131;nflammation and systemic diseases related to pseudoexfoliation?</article-title><source>J Glaucoma</source><year>2020</year><volume>29</volume><fpage>1077</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">32769729</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yildirim</surname><given-names>Z</given-names></name>
<name><surname>Yildirim</surname><given-names>F</given-names></name>
<name><surname>U&#x000e7;gun</surname><given-names>NI</given-names></name>
<name><surname>Sepici-Din&#x000e7;el</surname><given-names>A</given-names></name></person-group><article-title>The role of the cytokines in the pathogenesis of pseudoexfoliation syndrome</article-title><source>Int J Ophthalmol</source><year>2013</year><volume>6</volume><fpage>50</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23550261</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vulovic</surname><given-names>TS</given-names></name>
<name><surname>Pavlovic</surname><given-names>SM</given-names></name>
<name><surname>Jakovljevic</surname><given-names>VL</given-names></name>
<name><surname>Janicijevic</surname><given-names>KB</given-names></name>
<name><surname>Zdravkovic</surname><given-names>NS</given-names></name></person-group><article-title>Nitric oxide and tumour necrosis factor alpha in the process of pseudoexfoliation glaucoma</article-title><source>Int J Ophthalmol</source><year>2016</year><volume>9</volume><fpage>1138</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">27588268</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>HY</given-names></name>
<name><surname>Lee</surname><given-names>MY</given-names></name>
<name><surname>Lee</surname><given-names>YC</given-names></name>
<name><surname>Shin</surname><given-names>HY</given-names></name></person-group><article-title>Impact of cardiovascular comorbidity on increased neutrophil-lymphocyte ratio in pseudoexfoliation syndrome</article-title><source>Medicine</source><year>2022</year><volume>101</volume><fpage>e29602</fpage><pub-id pub-id-type="pmid">35839065</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bashir</surname><given-names>J</given-names></name>
<name><surname>Beg</surname><given-names>DT</given-names></name>
<name><surname>Beigh</surname><given-names>AA</given-names></name>
<name><surname>Wani</surname><given-names>EA</given-names></name></person-group><article-title>Red cell distribution width levels in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma</article-title><source>Indian J Ophthalmol</source><year>2022</year><volume>70</volume><fpage>2902</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">35918940</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>P</given-names></name>
<name><surname>Wang</surname><given-names>JJ</given-names></name>
<name><surname>Smith</surname><given-names>W</given-names></name></person-group><article-title>Association of pseudoexfoliation syndrome with increased vascular risk</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>685Y7</fpage><pub-id pub-id-type="pmid">9372724</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melese</surname><given-names>EK</given-names></name>
<name><surname>Shibeshi</surname><given-names>MA</given-names></name>
<name><surname>Sherief</surname><given-names>ST</given-names></name></person-group><article-title>Prevalence of pseudoexfoliation among adults and &#x00131;ts related ophthalmic variables in southern ethiopia: A cross-sectional study</article-title><source>Clin Ophthalmol</source><year>2022</year><volume>16</volume><fpage>3951</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">36471727</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yildirim</surname><given-names>N</given-names></name>
<name><surname>Yasar</surname><given-names>E</given-names></name>
<name><surname>Gursoy</surname><given-names>H</given-names></name>
<name><surname>Colak</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of pseudoexfoliation syndrome and its association with ocular and systemicdiseases in Eskisehir, Turkey</article-title><source>Int J Ophthalmol</source><year>2017</year><volume>10</volume><fpage>128</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">28149789</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naumann</surname><given-names>GO</given-names></name>
<name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name>
<name><surname>Kuchle</surname><given-names>M</given-names></name></person-group><article-title>Pseudoexfoliation syndrome for the comprehensiveo phthalmologist. Intraocular and systemic manifestations</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>951</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">9627642</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ya&#x0015f;ar</surname><given-names>E</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>N</given-names></name>
<name><surname>Atalay</surname><given-names>E</given-names></name></person-group><article-title>Pseudoexfoliation syndrome and antidepressant drug use</article-title><source>Turk J Ophthalmol</source><year>2019</year><volume>49</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">30829017</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shabani</surname><given-names>F</given-names></name>
<name><surname>Farasat</surname><given-names>A</given-names></name>
<name><surname>Mahdavi</surname><given-names>M</given-names></name>
<name><surname>Gheibi</surname><given-names>N</given-names></name></person-group><article-title>Calprotectin (S100A8/S100A9): A key protein between in flammation and cancer</article-title><source>Inflamm Res</source><year>2018</year><volume>67</volume><fpage>801</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">30083975</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Wu</surname><given-names>P</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: A meta-analysis</article-title><source>Biomark Med</source><year>2022</year><volume>16</volume><fpage>1239</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">36661047</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inciarte-Mundo</surname><given-names>J</given-names></name>
<name><surname>Frade-Sosa</surname><given-names>B</given-names></name>
<name><surname>Sanmart&#x000ed;</surname><given-names>R</given-names></name></person-group><article-title>Frombenchtobedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1001025</fpage><pub-id pub-id-type="pmid">36405711</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Miao</surname><given-names>S</given-names></name>
<name><surname>Qiu</surname><given-names>X</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn&#x02019;s disease</article-title><source>Medicine (Baltimore)</source><year>2022</year><volume>101</volume><fpage>e31163</fpage><pub-id pub-id-type="pmid">36281159</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Candar</surname><given-names>T</given-names></name>
<name><surname>Baklac&#x00131;</surname><given-names>D</given-names></name>
<name><surname>Kuzucu</surname><given-names>&#x00130;</given-names></name>
<name><surname>Kayaba&#x0015f;&#x00131;</surname><given-names>SA</given-names></name></person-group><article-title>Proinflammatory marker in chronicrhinosinusitis: Serum calprotectin</article-title><source>Acta Biochim Pol</source><year>2020</year><volume>67</volume><fpage>367</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">32865947</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Topuz</surname><given-names>MF</given-names></name>
<name><surname>Binnetoglu</surname><given-names>A</given-names></name>
<name><surname>Yumusakhuylu</surname><given-names>AC</given-names></name>
<name><surname>Sar&#x00131;</surname><given-names>M</given-names></name>
<name><surname>Baglam</surname><given-names>T</given-names></name>
<name><surname>Gerin</surname><given-names>F</given-names></name></person-group><article-title>Circulating calprotectin as a biomarker of laryngeal carcinoma</article-title><source>Eur Arch Otorhinolaryngol</source><year>2017</year><volume>274</volume><fpage>2499</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">28251322</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abd El Meged Nage</surname><given-names>S</given-names></name>
<name><surname>Esmail</surname><given-names>A</given-names></name></person-group><article-title>Calprotectin as a biomarker for diagnosis and severity of acute noninfectious anterior uveitis in egyptian patients</article-title><source>Clin Ophthalmol</source><year>2022</year><volume>16</volume><fpage>4109</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">36536923</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>RY</given-names></name>
<name><surname>Jia</surname><given-names>HM</given-names></name>
<name><surname>Han</surname><given-names>YZ</given-names></name>
<name><surname>Qian</surname><given-names>BS</given-names></name>
<name><surname>You</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>XK</given-names></name>
<etal/></person-group><article-title>Calprotectin as a diagnostic marker for sepsis: A meta-analysis</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><fpage>1045636</fpage><pub-id pub-id-type="pmid">36519133</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y</given-names></name>
<name><surname>Dai</surname><given-names>W</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>He</surname><given-names>X</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Neutrophil-to-platelet ratio predicts mortality following percutaneouscoronaryintervention in patients with acute ST-elevation myocardial infarction</article-title><source>Front Physiol</source><year>2022</year><volume>13</volume><fpage>1011048</fpage><pub-id pub-id-type="pmid">36200052</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Liang</surname><given-names>W</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>High neutrophil-to-platelet ratio &#x00131;s associated with poor survival in patients with acute aortic dissection</article-title><source>Dis Markers</source><year>2022</year><volume>2022</volume><fpage>5402507</fpage><pub-id pub-id-type="pmid">35774849</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<name><surname>Hui</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>A high neutrophil-to-platelet ratio is associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage: A retrospective study</article-title><source>BMC Neurol</source><year>2023</year><volume>23</volume><fpage>27</fpage><pub-id pub-id-type="pmid">36653741</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozkan</surname><given-names>D</given-names></name>
<name><surname>Altan</surname><given-names>C</given-names></name>
<name><surname>Er</surname><given-names>MO</given-names></name>
<name><surname>Gultekin</surname><given-names>F</given-names></name>
<name><surname>Kura&#x0015f;</surname><given-names>S</given-names></name>
<name><surname>Artunay</surname><given-names>O</given-names></name></person-group><article-title>The role of oxidative status in the pathogenesis of primary open-angle glaucoma, pseudoexfolyation syndrome and glaucoma</article-title><source>Eur J Ophthalmol</source><year>2023</year><volume>33</volume><fpage>352</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">35818741</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zenkel</surname><given-names>M</given-names></name>
<name><surname>Lewczuk</surname><given-names>P</given-names></name>
<name><surname>J&#x000fc;nemann</surname><given-names>A</given-names></name>
<name><surname>Kruse</surname><given-names>FE</given-names></name>
<name><surname>Naumann</surname><given-names>GO</given-names></name>
<name><surname>Schl&#x000f6;tzer-Schrehardt</surname><given-names>U</given-names></name></person-group><article-title>Proinflammatory cytokines are involved in the initiation of the abnormal matrixprocess in pseudoexfoliation syndrome/glaucoma</article-title><source>Am J Pathol</source><year>2010</year><volume>176</volume><fpage>2868</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">20395431</pub-id>
</element-citation></ref></ref-list></back></article>